HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Phase 3

Not yet recruiting

• Conditions: Pancreatic Cancer
• Interventions: Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate; Drug: gemcitabine; capecitabine

• Registration Number: NCT06217042
• Lead Sponsor: Fudan University

Brief Summary

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to gemcitabine + capecitabine treatment as adjuvant therapy in patients with resected pancreatic cancer.

Detailed Description

STUDY DESIGN/ Evaluation criteria Main criterion: efficacy. The main criterion is the disease-free survival. Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Patients without event at the time of analysis will be censored at the date of last follow-up visit.

Secondary criteria include Overall survival. OS is defined as the time from date of randomization until the date of death from any cause. Patients who are still living at the time of analysis will be censored at the date of last follow-up visit.

Secondary criteria also include 3-year disease-free survival rate/overall survival rate and 5-year disease-free survival rate/overall survival rate.

Tolerance Patients evaluable for toxicity must have received one investigational drug.

Study Timeline

• Status Verified: 2024-01
• Study First Submitted: 2024-01-10
• Study First Submitted QC: 2024-01-18
• Last Update Submitted: 2024-01-18
• Study First Posted: 2024-01-22
• Last Update Posted: 2024-01-22
• Study Start: 2024-02-05
• Primary Completion: 2027-03-30
• Study Completion: 2028-07-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 524

Inclusion Criteria

1. ECOG performance status 0 or 1
2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
3. Life expectancy of greater than or equal to 6 months.
4. Full recovery from surgery and patient is scheduled to start treatment within 3 weeks to 12 weeks after surgery.
5. Acceptable hematology parameters and blood chemistry levels.
6. Able and willing to provide a written informed consent.

Exclusion Criteria

1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;
2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma.
3. CA 19-9> 180 U / ml within 21 days of registration on study.
4. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma.
5. Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;
6. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within 6 months; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HR070803+Oxaliplatin+5-FU/LV	HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate	HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
GX	gemcitabine; capecitabine	gemcitabine; capecitabine

Primary Outcome Measures

Name	Time	Method
Disease-free survival (DFS)	From study start until 338 DFS events have occurred (approximately 21 months after last patient enrollment)	Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause.

Secondary Outcome Measures

Name	Time	Method
3-year disease-free survival rate	up to 36 months following the date the first patient was randomized	Disease-free survival within 3 years
Overall survival (OS)	From date of randomization until the date of death from any cause, assessed up to 37 months	OS is defined as the time from date of randomization until the date of death from any cause.
5-year disease-free survival rate	up to 60 months following the date the first patient was randomized	Disease-free survival within 5 years
3-year overall survival rate	up to 36 months following the date the first patient was randomized	Overall survival within 3 years
5-year overall survival rate	up to 60 months following the date the first patient was randomized	Overall survival within 5 years

Trial Locations

Locations (1)

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 🇨🇳 Shanghai, Shanghai, China